Leerink Partners Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $19
Tango Therapeutics: A Buy Rating on PRMT5 Inhibitor Prospects and Upcoming Clinical Data
Piper Sandler Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $18
Barclays Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $13
Barclays Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $13
HC Wainwright & Co. Reiterates Buy on Tango Therapeutics, Maintains $13 Price Target
Tango Therapeutics Analyst Ratings
H.C. Wainwright Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $13
Tango Therapeutics: A Buy Rating Amidst Competitive Advantages and Promising Market Valuation
Piper Sandler Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $18
Barclays Maintains Tango Therapeutics(TNGX.US) With Buy Rating, Maintains Target Price $13
Barclays Issues a Buy Rating on Tango Therapeutics (TNGX)
Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (TNGX), Inozyme Pharma (INZY) and Foghorn Therapeutics (FHTX)
Tango Therapeutics Analyst Ratings
Buy Rating Affirmed for Tango Therapeutics Amid Strong Financials and Promising Drug Pipeline
Wedbush Adjusts Price Target on Tango Therapeutics to $13 From $11, Maintains Outperform Rating
Tango Therapeutics Analyst Ratings
Jefferies Initiates Tango Therapeutics at Buy With $19 Price Target
Tango Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Tango Therapeutics, Maintains $13 Price Target